Lake Street lowered the firm's price target on P3 Health Partners to $12.50 from $20 and keeps a Buy rating on the shares. Though Q3 aEBITDA results were "disappointing," P3 is "making progress, even if it is not yet evident in reported results," which should point to a much-improved 2026, the analyst tells investors.
